These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10819708)

  • 1. Using cost-effectiveness analysis to target cholesterol reduction.
    Garber AM
    Ann Intern Med; 2000 May; 132(10):833-5. PubMed ID: 10819708
    [No Abstract]   [Full Text] [Related]  

  • 2. Using cost-effectiveness to target cholesterol reduction.
    Beaird J
    Ann Intern Med; 2001 Aug; 135(4):299-300. PubMed ID: 11511147
    [No Abstract]   [Full Text] [Related]  

  • 3. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
    MacNeil P
    Can J Cardiol; 1998 Apr; 14 Suppl A():14A-16A. PubMed ID: 9594928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study.
    Hilleman DE; Heineman SM; Foral PA
    Pharmacotherapy; 2000 Jul; 20(7):819-22. PubMed ID: 10907971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
    Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
    Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
    Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K
    JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Trial design.
    Black D; Davidson M; Koren M; Bakker-Arkema R; Tresh P; McLain R; Smith D; Hunninghake D
    Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):278-85. PubMed ID: 10170452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea.
    Jeong YJ; Kim H; Baik SJ; Kim TM; Yang SJ; Lee SH; Cho JH; Lee H; Yim HW; Choi IY; Yoon KH; Kim HS
    J Clin Pharm Ther; 2017 Jun; 42(3):292-300. PubMed ID: 28251662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. By the way, doctor. I have high cholesterol, and have been taking Mevacor (lovastatin) for two years. Recently, I was switched to Pravachol (pravastatin) because my insurance company would no longer pay for Mevacor. Is it as good?
    Nicholson CR
    Harv Womens Health Watch; 1999 Jun; 6(10):8. PubMed ID: 10233830
    [No Abstract]   [Full Text] [Related]  

  • 11. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
    Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
    JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of hypercholesterolemia with statins].
    Erikssen J; Madsen S
    Tidsskr Nor Laegeforen; 1997 Sep; 117(22):3216-20. PubMed ID: 9411860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization.
    Spearman ME; Summers K; Moore V; Jacqmin R; Smith G; Groshen S
    Clin Ther; 1997; 19(3):582-602; discussion 538-9. PubMed ID: 9220221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
    Usher-Smith JA; Ramsbottom T; Pearmain H; Kirby M
    Int J Clin Pract; 2007 Jan; 61(1):15-23. PubMed ID: 17229176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of a compliance-enhancing intervention in patients with hypercholesterolemia: design and baseline results of the Open Label Primary Care Study: Rosuvastatin Based Compliance Initiatives To Achievements of LDL Goals (ORBITAL) study.
    Willich SN; Müller-Nordhorn J; Sonntag F; Völler H; Meyer-Sabellek W; Wegscheider K; Windler E; Katus H
    Am Heart J; 2004 Dec; 148(6):1060-7. PubMed ID: 15632894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
    Cook JR; Yin D; Alemao E; Drummond M
    Pharmacoeconomics; 2004; 22 Suppl 3():37-48. PubMed ID: 15669152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness and Budget Impact of Treatment with Evolocumab Versus Statins and Ezetimibe for Hypercholesterolemia in Spain.
    Olry de Labry Lima A; Gimeno Ballester V; Sierra Sánchez JF; Matas Hoces A; González-Outón J; Alegre Del Rey EJ
    Rev Esp Cardiol (Engl Ed); 2018 Dec; 71(12):1027-1035. PubMed ID: 29937273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [When cholesterol lowering drugs should not be too expensive. Statins are especially effective in secondary prevention].
    Thomas HP; Kassner U; Steinhagen-Thiessen E
    MMW Fortschr Med; 2000 Jul; 142(30):33-4. PubMed ID: 10955017
    [No Abstract]   [Full Text] [Related]  

  • 19. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
    Weizel A; Sawicki PT
    MMW Fortschr Med; 2004 Dec; 146(51-52):14, 16. PubMed ID: 15675236
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.